BioInvent: Sells Asset for USD20+10m - Redeye
Bildkälla: Stockfoto

BioInvent: Sells Asset for USD20+10m - Redeye

Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab. This provides BioInvent with income and prolongs its financial runway further into 2026.

Redeye endorses BioInvent's divestment of its royalty and milestone rights to mezagitamab. This provides BioInvent with income and prolongs its financial runway further into 2026.
Börsvärldens nyhetsbrev